Global branded generics market is expected to rise from its initial estimated value of USD 232.83 billion in 2018 to a projected value of USD 421.15 billion by 2026, registering a CAGR of 7.69% in the forecast period of 2019-2026. This rise in market value can be attributed to growing need for cheaper treatment options and pharmaceutical drugs required by patients.
Download Sample Report With All Graphs & Charts: https://databridgemarketresearch.com/request-a-sample/?dbmr=global-branded-generics-market
Branded generic can be defined as those pharmaceutical drugs that have been re-released with a different brand name. These drugs are produced by various pharmaceutical manufacturing companies as the patent of this drug has already expired and the generic drugs are sold at a lower cost. Even though, there isn’t any difference in the quality or manufacturing process of the drug.
Key Market Competitors: Global Branded Generics Market
Teva Pharmaceutical Industries Ltd.; Zydus Cadila; Hetero; AstraZeneca; Mylan N.V.; Novartis AG; Pfizer Inc.; GlaxoSmithKline plc; Aspen Holdings; Bausch Health; Eris Lifesciences Limited; Par Pharmaceutical; Sanofi; Apotex Inc.; Dr. Reddy’s Laboratories Ltd.; Abbott; Sun Pharmaceutical Industries Ltd.; Lupin Pharmaceuticals, Inc.; ALLERGAN; Stada Arzneimittel; Cipla Inc. and EVA PHARMA are few of the major competitors currently working in the branded generics market.
Growth in the number of patents expired and expiring for the branded drugs; this factor is one of the major factors driving the market growth
Growth in the incidents and population suffering from chronic diseases and disorders; this factor is expected to drive the market growth
Key Developments in the Market:
In January 2019, Hetero announced the launch of generic version of “lapatinib” in India, which will be commercialized as “Hertab” by Hetero Healthcare Ltd.
In February 2018, Hetero announced the launch of a generic fixed-dose combination (FDC) drug of “emtricitabine” and “tenofovir alafenamide” in India. The product has already been approved by Drug Controller General of India (DCGI) will be commercialized as “Tafero-EM” by Hetero Healthcare Ltd.
In November 2017, Eris Lifesciences Limited announced that they had agreed to acquire the branded generics division of Strides Shasun Limited. This acquisition will help in establishing Eris Lifesciences Limited as one of the top ten companies worldwide for Central Nervous System treatment segment.
Get TOC For Full Analysis Of Report: https://databridgemarketresearch.com/toc/?dbmr=global-branded-generics-market
Segmentation: Global Branded Generics Market
By Product Type
Value-Added Branded Generics
Trade (Brand) Named Generics
By Therapeutic Application
Analgesics & Anti-Inflammatory
By Drug Class
Lipid Lowering Drugs
By Consumption Type
By Distribution Channel
North America (U.S., Canada, Mexico)
South America (Brazil, Argentina, Rest of South America)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe)
Asia-Pacific ( Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific)
Middle East & Africa (South Africa, Egypt, Saudi Arabia, United Arab Emirates, Israel, Rest of Middle East & Africa)
Want Full Report? Enquire Here: https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-branded-generics-market
Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing Corporatesales@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725